可利霉素通过抑制AXL/c-Met/c-Myc信号轴调控肝内胆管细胞癌细胞恶性行为的机制

doi:10.3969/j.issn.1006-5725.2025.15.003

Abstract

Abstract:

Objective The effects of carrimycin （CAM） on the biological functions of intrahepatic cholangiocarcinoma HuCCT1 cells were examined through in vitro experiments， and a preliminary investigation was conducted into its mechanism of action. Methods The intrahepatic cholangiocarcinoma cell line HuCCT1 was selected for the study. The effect of CAM on cell viability was assessed using the CCK-8 assay， and the IC₅₀ concentration was determined accordingly. The impact of CAM on cell migration was evaluated through a scratch wound healing assay. In addition， the effect of CAM on clonogenic ability was examined using a colony formation assay. Cell invasion capacity was assessed using a Transwell invasion assay. Flow cytometry was employed to analyze the effect of CAM on cell cycle progression. Furthermore， Western blotting was conducted to evaluate the expression levels of key proteins associated with epithelial-mesenchymal transition and the cell cycle. Finally， the influence of CAM on the AXL/c-Myc/c-Met signaling axis was also investigated. Results Compared with the control group， CAM significantly inhibited the proliferation of HuCCT1 cells in a concentration-dependent manner （P < 0.05）. Plate cloning assays demonstrated that CAM markedly suppressed the colony-forming ability of HuCCT1 cells （P < 0.05）. Scratch wound healing assays confirmed that CAM treatment significantly reduced the migration speed and narrowed the migration area of HuCCT1 cells （P < 0.05）. Flow cytometry analysis revealed that CAM treatment led to a significant increase in the proportion of cells in the G₀/G₁ phase and a decrease in the S phase （P < 0.05）. Western blot analysis further confirmed that the expression levels of key regulatory proteins CCND1 and CDK4， which are involved in the G_1/S phase transition， were down-regulated， while the expression of p21 was up-regulated （P < 0.05）. Transwell invasion assays indicated that CAM inhibited the invasive capacity of HuCCT1 cells. Consistently， Western blot results showed that E-Cadherin expression was increased （P < 0.05）， whereas the expression levels of N-Cadherin and Vimentin were decreased （P < 0.05）. Moreover， Western blot analysis verified that the expression of AXL， c-Met， and c-Myc was up-regulated in HuCCT1 cells treated with AXL recombinant protein （P < 0.05）. However， co-treatment with CAM and AXL recombinant protein significantly attenuated the expression of these proteins （P < 0.05）. Conclusions CAM inhibits the proliferation， migration， and invasion of intrahepatic cholangiocarcinoma HuCCT1 cells， thereby demonstrating antitumor effects， which may be associated with the AXL/c-Met/c-Myc signaling pathway.

Key words: intrahepatic cholangiocarcinoma, cell proliferation, cell cycle, epithelial-mesenchymal transition

CLC Number:

R730.5

Tongshu WANG,Min ZHOU,Huimin LIU,Hongxin PIAO. Carrimycin modulates malignant behavior of intrahepatic cholangiocarcinoma cells through inhibition of the AXL/c⁃Met/c⁃Myc signaling axis[J]. The Journal of Practical Medicine, 2025, 41(15): 2304-2310.

Figures/Tables 10

Fig.1

Fig.2

Tab.1

Fig.3

Fig.4

Tab.2

Fig.5

Tab.3

Tab.4

Fig.6

References 26

[1]	SIEGEL R L， MILLER K D， FUCHS H E， et al. Cancer statistics， 2022［J］. CA Cancer J Clin， 2022， 72（1）：7-33. doi:10.3322/caac.21708 doi: 10.3322/caac.21708
[2]	SAHA S K， ZHU A X， FUCHS C S， et al. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.： Intrahepatic Disease on the Rise［J］. Oncologist， 2016， 21（5）：594-599. doi:10.1634/theoncologist.2015-0446 doi: 10.1634/theoncologist.2015-0446
[3]	MAZZAFERRO V， GORGEN A， ROAYAIE S， et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma ［J］. J Hepatol， 2020， 72（2）：364-377. doi:10.1016/j.jhep.2019.11.020 doi: 10.1016/j.jhep.2019.11.020
[4]	LOWERY M A， BURRIS H A 3rd， JANKU F， et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma： a phase 1 study ［J］. Lancet Gastroenterol Hepatol， 2019， 4（9）：711-720. doi:10.1016/s2468-1253(19)30189-x doi: 10.1016/s2468-1253(19)30189-x
[5]	RAMASWAMY A， BHARGAVA P， SRINIVAS S， et al. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma （BEER BTC）： A Multicenter， Open-Label， Randomized， Phase II Trial ［J］. J Clin Oncol， 2024， 42（27）：3218-3227. doi:10.1200/jco.23.02420 doi: 10.1200/jco.23.02420
[6]	郝天怡，赫卫清. 大环内酯类抗生素代谢工程的研究进展［J］.生物工程学报，2021，37（5）：1737-1747.
[7]	LI X Y， LUO Y T， WANG Y H， et al. Anti-inflammatory effect and antihepatoma mechanism of carrimycin ［J］. World J Gastroenterol， 2023， 29（14）：2134-2152. doi:10.3748/wjg.v29.i14.2134 doi: 10.3748/wjg.v29.i14.2134
[8]	JIN Y， ZUO H X， LI M Y， et al. Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo ［J］. Front Pharmacol， 2021， 12：774231. doi:10.3389/fphar.2021.774231 doi: 10.3389/fphar.2021.774231
[9]	LIANG S Y， ZHAO T C， ZHOU Z H， et al. Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo［J］. Transl Oncol， 2021， 14（6）：101074. doi:10.1016/j.tranon.2021.101074 doi: 10.1016/j.tranon.2021.101074
[10]	KALYUKINA M， YOSAATMADJA Y， MIDDLEDITCH M J， et al. TAS-120 Cancer Target Binding： Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 （FGFR1） Irreversible Structure［J］. Chem Med Chem， 2019， 14（4）：494-500. doi:10.1002/cmdc.201800719 doi: 10.1002/cmdc.201800719
[11]	HIDALGO M， ROWINSKY E K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy ［J］. Oncogene， 2000， 19（56）：6680-6686. doi:10.1038/sj.onc.1204091 doi: 10.1038/sj.onc.1204091
[12]	田露，薛仁政，张志敏，等. 抗癌药物埃博霉素的生产及工艺发展［J］. 生物技术通报， 2019， 35 （10）： 198-204.
[13]	CHENG H， HUANG H， HUANG G. Synthesis and antitumor activity of epothilone B ［J］. Eur J Med Chem， 2018，157：925-934. doi:10.1016/j.ejmech.2018.08.055 doi: 10.1016/j.ejmech.2018.08.055
[14]	LIU Z， HUANG M， HONG Y， et al. Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway ［J］. Int J Biol Sci， 2022， 18（9）：3714-3730. doi:10.7150/ijbs.69989 doi: 10.7150/ijbs.69989
[15]	杨子荣，杨璇，倪婷婷，等. 可利霉素通过调控巨噬细胞极化影响黑色素瘤的增殖［J］. 中国生物工程杂志，2022，42（7）：12-23.
[16]	CHAN C Y， YUEN V W， CHIU D K， et al. Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity ［J］. Hepatology， 2023， 77（3）：729-744. doi:10.1002/hep.32461 doi: 10.1002/hep.32461
[17]	PANDIT B， ROYZEN M. Recent Development of Prodrugs of Gemcitabine ［J］. Genes （Basel）， 2022， 13（3）：466. doi:10.3390/genes13030466 doi: 10.3390/genes13030466
[18]	YAN X， WANG D， NING Z， et al. Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest ［J］. Discov Oncol， 2023， 14（1）：26. doi:10.1007/s12672-023-00631-4 doi: 10.1007/s12672-023-00631-4
[19]	刘娟娟，戴剑漉，高晓杰，等. 可利霉素体外抗结肠癌活性的研究［J］. 药物分析杂志，2022，42（7）：1142-1152.
[20]	白丽娜，刘颖，唐春晓，等. 可利霉素对胰腺癌细胞生物学功能的影响［J］. 临床肝胆病杂志，2022，38（12）：2793-2801.
[21]	DU Z， LOVLY C M. Mechanisms of receptor tyrosine kinase activation in cancer ［J］. Mol Cancer， 2018， 17（1）：58. doi:10.1186/s12943-018-0782-4 doi: 10.1186/s12943-018-0782-4
[22]	HSU C H， HUANG Y H， LIN S M， et al. AXL and MET in Hepatocellular Carcinoma： A Systematic Literature Review ［J］. Liver Cancer， 2022， 11（2）：94-112. doi:10.1159/000520501 doi: 10.1159/000520501
[23]	SUN X， CHEN H， YOU S， et al. AXL upregulates c-Myc expression through AKT and ERK signaling pathways in breast cancers ［J］. Mol Clin Oncol， 2023， 18（3）：22. doi:10.3892/mco.2023.2618 doi: 10.3892/mco.2023.2618
[24]	YEH C Y， SHIN S M， YEH H H， et al. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer ［J］. BMC Cancer， 2011， 11（1）：139. doi:10.1186/1471-2407-11-139 doi: 10.1186/1471-2407-11-139
[25]	LIU Z， WANG Z， CHEN D， et al. Paeoniflorin Inhibits EMT and Angiogenesis in Human Glioblastoma via K63-Linked C-Met Polyubiquitination-Dependent Autophagic Degradation ［J］. Front Oncol， 2022， 12：785345. doi:10.3389/fonc.2022.785345 doi: 10.3389/fonc.2022.785345
[26]	RAHNEMAI-AZAR A A， ABBASI A， ACHER A W， et al. Emerging pathways for precision medicine in management of cholangiocarcinoma ［J］. Surg Oncol， 2020， 35：47-55. doi:10.1016/j.suronc.2020.08.008 doi: 10.1016/j.suronc.2020.08.008

项目	对照组	4 μg/mL CAM
24 h迁移率	27.68 ± 1.32	12.43 ± 1.38^*
48 h迁移率	69.39 ± 1.21	44.58 ± 1.25^*
72 h迁移率	82.53 ± 0.84	54.04 ± 1.03^*

组别	CCND1	CDK4	p21
对照组	0.19 ± 0.01	0.23 ± 0.01	0.13 ± 0.01
4 μg/mL CAM	0.14 ± 0.02^*	0.15 ± 0.02^*	0.20 ± 0.01^*

组别	E-Cadherin	N-Cadherin	Vimentin
对照组	0.26 ± 0.02	0.35 ± 0.01	0.49 ± 0.02
4 μg/mL CAM	0.32 ± 0.01^?	0.27 ± 0.03^?	0.35 ± 0.01^?

组别	AXL	c-Met	c-Myc
对照组	0.25 ± 0.01	0.16 ± 0.01	0.41 ± 0.01
rAXL	0.32 ± 0.01^*	0.26 ± 0.01^*	0.92 ± 0.01^*
CAM+rAXL	0.27 ± 0.02^#	0.19 ± 0.01^#	0.67 ± 0.02^#

Carrimycin modulates malignant behavior of intrahepatic cholangiocarcinoma cells through inhibition of the AXL/c⁃Met/c⁃Myc signaling axis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 26

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeping HE,Junming XU. The role and prognostic value of matrix metalloproteinase 19 in colorectal cancer and its liver metastasis [J]. The Journal of Practical Medicine, 2025, 41(13): 1987-1996.
[2]	Chang ZHANG,Chunshan LIU,Huaying LIAO,Yuchao WU,Yunhong TIAN. The effect of pseudouracil modifying enzyme 3 activating AKT pathway on malignant progression of glioblastoma [J]. The Journal of Practical Medicine, 2025, 41(12): 1825-1834.
[3]	Wenxin LI,Minjun LU,Li LIN,Yueqin LIU,Xiaolan. ZHU. circRAF1 regulates the proliferation and apoptosis of human ovarian granulosa cells [J]. The Journal of Practical Medicine, 2024, 40(7): 910-917.
[4]	Chunfang KONG,Anna LI,Bo KE,Weirong DING,Tingting LIU,Huan FU,Tingting ZHANG,Chenghao JIN,Mei. WU. The inhibitory effect and molecular mechanism of 6-gingerol on human multiple myeloma cells [J]. The Journal of Practical Medicine, 2024, 40(23): 3291-3297.
[5]	WENG Xu, WU Donghui, MA Wentao, PENG He.. lncRNA PCAT19 targeted miR ⁃769⁃5p promotes the proliferation，migration and invasion of oral squa⁃ mous cell carcinoma HSC3 cells [J]. The Journal of Practical Medicine, 2023, 39(4): 417-422.
[6]	Haiying LIU,Feng CHEN,Jia. YAO. Suppression of miR-767-5p expression of inhibits breast cancer cell proliferation， migration， invasion and EMT through down-regulating IGF1 [J]. The Journal of Practical Medicine, 2023, 39(22): 2878-2884.
[7]	Yuling LI,Jianlin YANG,Zhi CUI,Jing WANG,Yafeng LV,Chunyu. CAO. Effect of BMI-1 inhibitor PTC-596 on proliferation， cell cycle， and apoptosis of human breast cancer MCF-7cells [J]. The Journal of Practical Medicine, 2023, 39(18): 2317-2322.
[8]	Sha YI,Nan HU,Yue LI,Lin YANG,Yuting ZHANG,Xia XIONG,Guishu ZHONG,Yan. CHEN. Role of peroxisome proliferator⁃activated receptors⁃γ in modulating P. acnes⁃induced pyroptosis， cell proliferation and apoptosis in human keratinocytes [J]. The Journal of Practical Medicine, 2023, 39(16): 2043-2049.
[9]	Cuixia HUANG,Yaqian ZHANG,Aiping YANG,Ruihanqiu LIU,Yan LU. Exploring the mechanism of using andrographolide to inhibit triple negative breast cancer based on Hippo/YAP signaling pathway [J]. The Journal of Practical Medicine, 2023, 39(16): 2050-2056.
[10]	LIANG Weijie, ZHANG Yaowei, WANG Yongjia, WENG Jiawen, ZHENG Yilin, DING Yi.. AIFM3 interferes the proliferation and migration of colorectal cancer cells by regulating STAT3 signaling pathway [J]. The Journal of Practical Medicine, 2022, 38(7): 821-827.
[11]	WEI Huizhen, YUN Wenjing, CUI Xichun.. Effects of METTL3 mediated IGF2BP3 m6A modification on proliferation and migration of hepatoblasto⁃ ma cells in children [J]. The Journal of Practical Medicine, 2022, 38(24): 3054-3058.
[12]	ZHU Zhiwen, YANG Liangfang, ZHENG Yang, HUANG Haili, HE Huijuan.. CDKN3 reduces the sensitivity of intrahepatic cholangiocarcinoma cells to cisplatin by regulating G2/M checkpoint [J]. The Journal of Practical Medicine, 2022, 38(22): 2768-2779.
[13]	WANG Ming, SA Rula, WANG Chaoqi, YAN Zhen.. miR ⁃let ⁃7c improves sperm quality mediating differentiation of spermatogonial stem cell in mice [J]. The Journal of Practical Medicine, 2022, 38(20): 2524-2530.
[14]	FAN Huili, ZHAO Ruhua, ZHANG He, LIN Xu, XUE Gang, WU Jingfang.. Expression and biological role of E2F7 in papillary thyroid carcinoma [J]. The Journal of Practical Medicine, 2022, 38(17): 2138-2144.
[15]	LI Liheng, WANG Rui, WANG Qin, ZHANG Zhiyi, AN Feng, ZHANG Xuan, WANG Xiaoming, ZHANG Fan.. Effect of miR ⁃ 498 targeting PCK1 on growth of oral squamous cell carcinoma cells [J]. The Journal of Practical Medicine, 2022, 38(11): 1339-1346.